Optimizing medication guidance support for patients with cancer pain: development and evaluation of a pharmaceutical care system for healthcare professionals.

Background: Effective management of cancer pain critically depends on timely medication administration and adherence to precise medication guidelines. In the context of limited time and a busy healthcare environment, tailoring the optimal medication schedule for each patient with cancer pain presents a significant challenge for physicians and clinical pharmacists.

Methods: To address this challenge, we conducted a comprehensive analysis of healthcare professionals' needs in guiding cancer pain medication.

Analysis of hemorrhagic drug-drug interactions between P-gp inhibitors and direct oral anticoagulants from the FDA Adverse Event Reporting System.

Background: Limited understanding exists regarding the hemorrhagic risk resulting from potential interactions between P-glycoprotein (P-gp) inhibitors and direct oral anticoagulants (DOACs). Utilizing the Food and Drug Administration Adverse Event Reporting System (FAERS) data, we analyzed hemorrhagic adverse events (AEs) linked with the co-administration of P-gp inhibitors and DOACs, aiming to offer guidance for their safe and rational use.

Methods: Hemorrhagic events associated with P-gp inhibitors in combination with DOACs were scrutinized from the FAERS database.

Post-Marketing Safety Concerns with Upadacitinib: A Disproportionality Analysis of the FDA Adverse Event Reporting system.

Background: Upadacitinib was approved to treat rheumatoid arthritis, psoriasis, ulcerative colitis, ankylosing spondylitis, and atopic dermatitis. This study assessed the adverse events (AEs) associated with upadacitinib by mining data from the US Food and Drug Administration Adverse Event Reporting System (FAERS).

Methods: Disproportionality analyses, including the reporting odds ratio (ROR), the proportional reporting ratio (PRR), the Bayesian confidence propagation neural network (BCPNN), and the multi-item gamma Poisson shrinker (MGPS) algorithms, were employed to quantify the signals of upadacitinib-associated AEs.

Selective Action Mechanism of Fenclorim on Rice and Is Associated with the Inducibility of Detoxifying Enzyme Activities and Antioxidative Defense.

Fenclorim (Fen) is a safener developed for pretilachlor (Pre) that can protect rice from injury caused by Pre but does not lower the weed control effects of Pre. Unfortunately, the mechanism of selective action of Fen between rice and weeds, such as (barnyard grass), has not been clarified. In this study, the differences in physiology, biochemistry, and gene transcription between rice and response to Fen were compared.

Effects of fenclorim on rice physiology, gene transcription and pretilachlor detoxification ability.

Background: Fenclorim (Fen) can effectively protect rice from pretilachlor (Pre) injury, but its effects on rice have not been formally evaluated; thus, the Fen mode of action for alleviating the phytotoxicity caused by Pre in rice is not clear. This study aimed to examine the biochemical and physiological effects of Fen on rice and to determine the changes induced by Fen at the transcriptome level.

Result: The chlorophyll content of rice plants was significantly affected by Pre but not by Fen.